Replies to post #141523 on PharmaCyte Biotech Inc (PMCB)

[longboarder7892]

I cant wait till we file the IND and then uplist to the NASDAQ. Looks like KW has been approached already once the AN IPO came out in the news. Get the IND filed and we fly......................I would love to see us trading on the NASD with a price well above $4.00

[PINKribbon]

LB...again, NOTHING matters, not even this news; good or bad, UNTIL the IND gets the FDAs blessing.

Patience


Go Team PharmaCyte!!!

[DragonBear]

We are also contemplating a reverse stock split

and a possible up-listing of our common stock to The Nasdaq Capital Market (“Nasdaq”).

Microcrap scams always contemplate uplisting, and it never occurs.

Nasdaq requires that the bid price of the common stock must have a closing bid price of at least $4.00 per share in connection with an up-listing.

They require a little more than that...


NASDAQ Capital Market requirements

PMCB ineligible under Standard 1: No earnings.

PMCB ineligible under Standard 2: No positive cash flow.

PMCB ineligible under Standard 3: Market Capitalization was not >= $850M over the previous 12 months. And again no revenue >$90M per 12 months.

PMCB ineligible under Standard 4: Current Market Cap is <$160M or approx $40.8M. A R/S does nothing to change that. One would need for Kenny to issue approx 4X the current number of shares to 8B, without the PPS going down with the massive dilution. Not happening. Not to mention there's another qualifier for Standard 4 - value of assets has to be at least $80M. Currently it's $8M.

There's a little more to it, than just R/Sing the shares up to $4 - isn't there?

Like I said, Kenny can tell SHs they are "contemplating" a R/S, and uplisting. The golden dream for all Microcrap SHs. But there's no way for PMCB to get there - another not happening.

[$Pistol Pete$]

Wow…10b shares increase and possible reverse split 100,000:1 before it get delisted

[Jimmy Joe]

We are also contemplating a reverse stock split and a possible up-listing of our common stock to The Nasdaq Capital Market (“Nasdaq”). Nasdaq requires that the bid price of the common stock must have a closing bid price of at least $4.00 per share in connection with an up-listing. An up-listing of our common stock to Nasdaq could potentially bring many benefits to the Company and its investors, including broadening the appeal of our shares to institutional investors, improving liquidity for our shareholders, potentially facilitating our ability to raise capital through offerings of our common stock and equity linked securities as well as increasing our visibility in the broader investment community. No assurance can be given that we will effect a reverse stock split and an uplisting of our common stock to Nasdaq.

Up listing this scam with a reverse split so that they can try to scam NASDAQ investors. Better yet get institutional buyers.... nobody is going to guy this crapola.

Reverse split will make this stock WORTHLESS. No revenues no anything...

IND to FDA on permanent HOLD.

scam......